Successful treatment of kaposiform hemangioendothelioma with everolimus.

Pediatric blood & cancer

PubMedID: 25306933

Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K. Successful treatment of kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer. 2014;.
There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1?mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE. Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc.